Skip to content

Comparing the effects of dexmedetomidine and propofol on sublingual microcirculation of the patients after cardiopulmonary bypass

Comparing the effects of dexmedetomidine and propofol on sublingual microcirculation of the patients after cardiopulmonary bypass

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006611
Enrollment
Unknown
Registered
2015-06-02
Start date
2015-06-18
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sedation after cardiac surgery

Interventions

Control group:Propofol

Sponsors

The First Affiliated Hospital, School of Medicine Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 150 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Selective cardiac surgery; 3. Used caridopulomonary bypass during operation; 4. Transferred into intensive care unit and need for invasive mechanical ventilation

Exclusion criteria

Exclusion criteria: 1. Acute severe neurological disorder; 2. Mean arterial pressure less than 55mmHg despite appropriate intravenous volume replacement and vasopressors; 3. Heart rate less than 50/min; 4. Atrioventricular-conduction grade II or III (unless pacemaker installed); 5. Of dexmedetomidine or propofol allergy or other contradications; 6. Diabetes patients with insulin dependent; 7. Body mass index(BMI)>= 30kg/m^2; 8. Second or more operations.

Design outcomes

Primary

MeasureTime frame
Sublingual microcirculation;SOFA score;APACHEII score;Complicaitoins after sedation during ICU stay;Serum lactate level;Length of ICU stay;Postoperative length of hospital stay;

Countries

China

Contacts

Public ContactFang Xiangming

The First Affiliated Hospital School of Medicine Zhejiang University

xiangming_fang@163.com+86 138 5716 1019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026